Advertisement

Transarterial Therapies for Benign and Malignant Liver Tumors

  • Suyash S. Kulkarni
  • Nitin Sudhakar Shetty
  • Shashank Mishra
  • David Narayan
Chapter
  • 44 Downloads

Abstract

The liver is the site for both benign lesions as well as primary and secondary malignancies. While surgery is generally avoided in benign neoplasm, a considerable proportion of patients are not eligible for curative surgical treatment despite advancement in surveillance and treatment options due to advanced tumor stage or poor hepatic functional reserve. The use of transarterial catheter-directed therapies in such patients has gained acceptance as a useful option to treat both benign and malignant liver tumors. Transarterial therapies involve treatment of tumors by injecting various agents into the hepatic artery which include bland embolization, transarterial chemoembolization, or radioembolization depending on the clinical presentation, type of tumor, and stage of the disease. While bland embolization essentially devascularizes the tumor, chemoembolization controls tumors by combining both chemotherapeutic effects of the antineoplastic drug along with ischemic necrosis due to arterial embolization. Radioembolization, on the other hand, acts on the tumor through radiation that is emitted by radiopharmaceutical beads injected into the tumor through the hepatic artery. In this chapter, the basic principles, techniques, complications, and follow-up assessments of various transarterial therapies for malignant and benign liver tumors are reviewed and clinical applicability briefed.

References

  1. 1.
    Kumar A, Srivastava DN, Chau TTM, Long HD, Bal C, Chandra P, et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology. 2007 May;243(2):509–19.CrossRefGoogle Scholar
  2. 2.
    Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal “capillarization” in dysplastic nodules of the liver. Am J Surg Pathol. 1998 Jun;22(6):656–62.CrossRefGoogle Scholar
  3. 3.
    Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol Off J Am Soc Clin Oncol. 1987 Nov;5(11):1836–40.CrossRefGoogle Scholar
  4. 4.
    Konno T, Maeda H, Yokoyama I, Iwai K, Ogata K, Tashiro S, et al. Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma. Gan To Kagaku Ryoho. 1982 Nov;9(11):2005–15.PubMedGoogle Scholar
  5. 5.
    Covey AM, Brody LA, Maluccio MA, et al. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology. 2002;224(2):542–7.CrossRefGoogle Scholar
  6. 6.
    Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics. 2005 Oct;25(suppl_1):S25–39.CrossRefGoogle Scholar
  7. 7.
    EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018 Jul 1;69(1):182–236.CrossRefGoogle Scholar
  8. 8.
    Raza A, Sood GK. Hepatocellular carcinoma review: current treatment and evidence-based medicine. World J Gastroenterol. 2014 Apr 21;20(15):4115–27.CrossRefGoogle Scholar
  9. 9.
    Vogl T, Gruber-Rouh T. HCC: Transarterial therapies—what the interventional radiologist can offer. Dig Dis Sci. 2019 Mar;5:64.Google Scholar
  10. 10.
    Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018, Jan;29(Suppl 4):iv 238–55.CrossRefGoogle Scholar
  11. 11.
    Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol. 2011 Oct;197(4):W562–70.CrossRefGoogle Scholar
  12. 12.
    Arslanoglu A, Seyal AR, Sodagari F, Sahin A, Miller FH, Salem R, et al. Current guidelines for the diagnosis and Management of Hepatocellular Carcinoma: a comparative review. Am J Roentgenol [Internet]. 2016 Aug 4 [cited 2019 Aug 3]; Available from https://www.ajronline.org/doi/full/10.2214/AJR.15.15490
  13. 13.
    Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterialradioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015 Jun 7;21(21):6518–25.CrossRefGoogle Scholar
  14. 14.
    Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of Tc-99m-MAA SPECT/CT liver perfusion imaging in treatment planning for Y-90-microsphere selective internal radiation treatment. J Nucl Med Off Publ Soc Nucl Med. 2010 Aug 1;51:1206–12.Google Scholar
  15. 15.
    Ma J, Gimenez JM, Sandow T, Devun D, Kirsch D, Gulotta P, et al. Intraarterial liver-directed therapies: the role of interventional oncology. Ochsner J. 2017;17(4):412–6.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol. 2015 Apr 18;7(5):738–52.CrossRefGoogle Scholar
  17. 17.
    Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, et al. TransarterialRadioembolization (TARE) agents beyond 90Y-microspheres [internet]. Bio Med Res Int. 2018 [cited 2019 Oct 6]. Available from: https://www.hindawi.com/journals/bmri/2018/1435302/
  18. 18.
    Cappelli A, Pettinato C, Golfieri R. Transarterialradioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma. 2014 Nov 3;1:163–82.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018 Dec;7(6):487–9.CrossRefGoogle Scholar
  20. 20.
    Zhang J, Xu F, Chen K, Zhou S, Li H, Niu C, et al. An effective approach for treating unresectable hepatoblastoma in infants and children: preoperative transcatheter arterial chemoembolization. Oncol Lett. 2013 Sep;6(3):850–4.CrossRefGoogle Scholar
  21. 21.
    Oue T, et al. Transcatheter arterial chemoembolization in the treatment of hepatoblastoma. 1998 Dec;33(12):1771–5. https://www.ncbi.nlm.nih.gov/pubmed/9869048
  22. 22.
    Arcement CM, Towbin RB, Meza MP, Gerber DA, Kaye RD, Mazariegos GV, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol. 2000 Nov;30(11):779–85.CrossRefGoogle Scholar
  23. 23.
    Mahnken A, Pereira P, de Baere T. Interventional oncologic approaches to liver metastases. Radiology. 2013 Feb 1;266:407–30.CrossRefGoogle Scholar
  24. 24.
    Gruber-Rouh T, Marko C, Thalhammer A, Nour-Eldin N-E, Langenbach M, Beeres M, et al. Current strategies in interventional oncology of colorectal liver metastases. Br J Radiol. 2016 Aug;89(1064):20151060.CrossRefGoogle Scholar
  25. 25.
    Kulkarni S, Shetty NS, Polnaya AM, Patil S, Gala K, Chivate R, et al. Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India. Indian J Radiol Imaging. 2017;27(2):200–6.CrossRefGoogle Scholar
  26. 26.
    de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, et al. GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015 Apr;172(4):R151–66.CrossRefGoogle Scholar
  27. 27.
    Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Interv Radiol. 2013 Mar;30(1):28–38.CrossRefGoogle Scholar
  28. 28.
    Khan W, Sullivan KL, McCann JW, Gonsalves CF, Sato T, Eschelman DJ, et al. Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. AJR Am J Roentgenol. 2011 Aug;197(2):W343–5.CrossRefGoogle Scholar
  29. 29.
    Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15;104(8):1590–602.CrossRefGoogle Scholar
  30. 30.
    Firouznia K, Ghanaati H, Alavian SM, Nassiri Toosi M, Ebrahimi Daryani N, Jalali AH, et al. Management of liver hemangioma using trans-catheter arterial embolization. Hepat Mon. 2014 Dec 25;14(12):e25788.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Liu X, Yang Z, Tan H, Huang J, Xu L, Liu L, et al. Long-term result of transcatheter arterial embolization for liver hemangioma. Medicine (Baltimore). 2017 Dec 1;96:e9029.CrossRefGoogle Scholar
  32. 32.
    Remiszewski P, Szczerba E, Kalinowski P, Gierej B, Dudek K, Grodzicki M, et al. Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation. World J Gastroenterol. 2014 Aug 28;20(32):11333–9.CrossRefGoogle Scholar
  33. 33.
    Daller J, Bueno J, Gutierrez J, Dvorchik I, Towbin R, Dickman P, et al. Hepatic hemangioendothelioma: clinical experience and management strategy. J Pediatr Surg. 1999 Feb 1;34:98–105.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2021

Authors and Affiliations

  • Suyash S. Kulkarni
    • 1
  • Nitin Sudhakar Shetty
    • 1
  • Shashank Mishra
    • 1
  • David Narayan
    • 1
  1. 1.Department of Interventional RadiologyTata Memorial Centre, Homi Bhabha National InstituteMumbaiIndia

Personalised recommendations